Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Economic evaluation · women with persistent, recurrent, or metastatic cervical cancer
1 finding from 1 review
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · women having endometriosis surgery
Postsurgical medical therapy may leads to lower disease recurrence ≤ 12 months (dichotomous) compared with placebo or no medical therapy (low certainty).
1 finding from 1 review
Disease recurrence ≤ 12 months (EEC stage) · women having endometriosis surgery
It is very uncertain whether postsurgical medical therapy changes disease recurrence ≤ 12 months (EEC stage) compared with placebo or no medical therapy (very low certainty).
1 finding from 1 review
Pregnancy rate · women having endometriosis surgery
Postsurgical medical therapy probably leads to higher pregnancy rate (dichotomous) compared with placebo or no medical therapy (moderate certainty).
1 finding from 1 review
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain recurrence (dichotomous) Pain recurrence ≤ 12 months · women having endometriosis surgery
Presurgical medical therapy showed no clear difference in pain recurrence (dichotomous) Pain recurrence ≤ 12 months compared with postsurgical medical therapy (low certainty).
1 finding from 1 review
Disease recurrence at 12 months – total (AFS score) · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease recurrence ≤ 12 months (EEC stage) · women having endometriosis surgery
It is very uncertain whether presurgical medical therapy changes disease recurrence ≤ 12 months (EEC stage) compared with postsurgical medical therapy (very low certainty).
1 finding from 1 review
Pregnancy rate · women having endometriosis surgery
It is very uncertain whether presurgical medical therapy changes pregnancy rate (dichotomous) compared with postsurgical medical therapy (very low certainty).
1 finding from 1 review